Strategic Appointments Propel VIS-101 Forward
In an exciting development for VIS-101, NovaBridge Biosciences has appointed two distinguished leaders in ophthalmology, Cadmus C. Rich, MD, MBA, as Chief Medical Officer and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board. Their expertise will significantly enhance the clinical development of this promising biologic, aimed at addressing complex retinal diseases.
Meet the New Leadership Team
Dr. Rich steps into the role of Chief Medical Officer with a wealth of experience from his previous leadership positions in prominent biotech firms. His role at Visara will entail overseeing all clinical functions and ensuring robust development of the VIS-101 program. Meanwhile, Dr. Quezada-Ruiz will lend his extensive background in retina-focused therapies as Chair of the Scientific Advisory Board, guiding innovations and strategic direction for clinical projects.
The Promise of VIS-101
VIS-101 is a next-generation bifunctional biologic designed to target VEGF-A and ANG-2, representing a potential breakthrough in the treatment of wet age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). With its innovative approach, VIS-101 may set a new industry standard due to its dual targeting mechanism that aims to enhance treatment durability and effectiveness.
Expert Quotes on the Future of VIS-101
Dr. Rich expressed enthusiasm about accelerating ophthalmic treatments through innovative clinical strategies, believing that VIS-101 could transform outcomes for patients with retinal diseases. Dr. Quezada-Ruiz echoed this sentiment, highlighting the existing unmet needs in retinal therapy and his eagerness to contribute to the advancement of VIS-101 through collaboration with the dedicated team at Visara.
NovaBridge's Vision and Commitment
These appointments not only underscore NovaBridge's commitment to its strategic transformation into a global biotech player but also demonstrate the company's dedication to enhancing value for stakeholders. Sean Fu, PhD, the Chief Executive Officer of NovaBridge, remarked on the successful execution of the company’s strategic initiatives and the growing momentum behind their innovative strategies, which aim to bridge cutting-edge science with practical applications to improve patient care.
About Dr. Cadmus C. Rich
Dr. Rich is a seasoned expert in ophthalmology and drug development, engaging in multiple successful clinical trials and overseeing critical drug approvals during his career. His academic journey included obtaining a medical degree from UNC/Chapel Hill, followed by extensive practice in various ophthalmologic specialties before stepping into executive roles within the biopharmaceutical industry.
About Dr. Carlos Quezada-Ruiz
Dr. Quezada-Ruiz is recognized for his influential role in retinal therapeutics, previously contributing to major drug development successes at leading companies such as Genentech. Currently involved in academic and advisory roles, he is focused on advancing innovative therapies for retinal diseases through strategic leadership and practical application of emerging technologies in the healthcare field.
The Regulatory Path for VIS-101
VIS-101 is currently undergoing a comprehensive Phase 2 clinical trial, with expectations to progress into Phase 3 trials in the near future. The outcomes of these studies are anticipated to further validate the efficacy and safety of this new treatment, setting the stage for potential regulatory approval.
Conclusion: Looking Ahead
With the appointments of Dr. Rich and Dr. Quezada-Ruiz, NovaBridge and Visara are strategically positioned to make significant advancements in the development of VIS-101. As a company committed to bridging science and innovation, the future looks bright for both the team and the patients who will benefit from these efforts.
Frequently Asked Questions
What is VIS-101?
VIS-101 is a novel bifunctional biologic targeting VEGF-A and ANG-2 to treat conditions like wet AMD, DME, and RVO.
Who are the new leaders appointed at Visara?
Cadmus C. Rich, MD, has been appointed as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board.
What experience do the new leaders bring?
Both leaders have extensive backgrounds in ophthalmology and drug development, contributing to numerous successful clinical programs.
When is VIS-101 expected to enter Phase 3 trials?
VIS-101 is anticipated to be Phase 3-ready around 2026.
What impact will these appointments have on NovaBridge?
These strategic appointments are expected to enhance NovaBridge's innovative capabilities, streamline clinical development processes, and improve patient outcomes.
